Literature DB >> 7525586

Identification of a receptor candidate for the carboxyl-terminal cell binding domain of thrombospondins.

A G Gao1, W A Frazier.   

Abstract

The carboxyl-terminal cell binding domain (CBD) of thrombospondin-1 (TS1) contains two cell attachment peptides, 4N1s (RFYVVMWK) and 7N3 (FIRVVMY-EGKK), which share the sequence VVM. These peptides, and more soluble derivatives have been radiolabeled with 125I and used in conjunction with a variety of membrane impermeant cross-linking reagents to identify and characterize receptor candidates on several cell types. All of the VVM containing peptides tested with five different cross-linking reagents specifically labeled a 52-kDa protein, which was also affinity labeled by the recombinant TS1 CBD. After cross-linking peptide to K562 cells to block the 52-kDa protein, both cell adhesion to and affinity labeling by VVM peptides were inhibited in a concentration-dependent manner. Peptide labeling, like cell adhesion, was partially inhibited by heparin and stimulated by EDTA. The 52-kDa protein did not appear to contain sulfated glycan chains and was trypsin sensitive. It was recovered in a membrane fraction and was readily solubilized with Triton X-100 and X-114. Upon phase separation of the Triton X-114, the 52-kDa protein partitioned into the hydrophobic detergent phase. The detergent-solubilized receptor candidate bound selectively to wheat germ agglutinin-Sepharose, and after cell surface labeling with a membrane impermeant biotinylating reagent, bound to streptavidin-Sepharose. Furthermore, fluorescent beads covalently derivatized with peptide specifically decorated intact K562 cells. Thus the properties of the 52-kDa protein are consistent with those of a receptor for the CBD of TS1 and other TS isoforms.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525586

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest.

Authors:  E Sick; A Jeanne; C Schneider; S Dedieu; K Takeda; L Martiny
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 2.  Structures of thrombospondins.

Authors:  C B Carlson; J Lawler; D F Mosher
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

Review 3.  CD47: a new target in cardiovascular therapy.

Authors:  Jeff S Isenberg; David D Roberts; William A Frazier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-10       Impact factor: 8.311

4.  Thrombospondin-1 (TSP1) contributes to the development of vascular inflammation by regulating monocytic cell motility in mouse models of abdominal aortic aneurysm.

Authors:  Zhenjie Liu; Stephanie Morgan; Jun Ren; Qiwei Wang; Douglas S Annis; Deane F Mosher; Jing Zhang; Christine M Sorenson; Nader Sheibani; Bo Liu
Journal:  Circ Res       Date:  2015-05-04       Impact factor: 17.367

5.  Diverse mutations in the gene for cartilage oligomeric matrix protein in the pseudoachondroplasia-multiple epiphyseal dysplasia disease spectrum.

Authors:  M D Briggs; G R Mortier; W G Cole; L M King; S S Golik; J Bonaventure; L Nuytinck; A De Paepe; J G Leroy; L Biesecker; M Lipson; W R Wilcox; R S Lachman; D L Rimoin; R G Knowlton; D H Cohn
Journal:  Am J Hum Genet       Date:  1998-02       Impact factor: 11.025

6.  Structure of the calcium-rich signature domain of human thrombospondin-2.

Authors:  C Britt Carlson; Douglas A Bernstein; Douglas S Annis; Tina M Misenheimer; Blue-leaf A Hannah; Deane F Mosher; James L Keck
Journal:  Nat Struct Mol Biol       Date:  2005-09-25       Impact factor: 15.369

Review 7.  CD47: role in the immune system and application to cancer therapy.

Authors:  Seyed Mohammad Gheibi Hayat; Vanessa Bianconi; Matteo Pirro; Mahmoud R Jaafari; Mahdi Hatamipour; Amirhossein Sahebkar
Journal:  Cell Oncol (Dordr)       Date:  2019-08-14       Impact factor: 6.730

Review 8.  Lessons from common markers of tumor-initiating cells in solid cancers.

Authors:  Olivier Gires
Journal:  Cell Mol Life Sci       Date:  2011-07-24       Impact factor: 9.261

9.  Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation.

Authors:  Thomas W Miller; Sukhbir Kaur; Kelly Ivins-O'Keefe; David D Roberts
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

Review 10.  Regulation of thrombospondin1 by extracellular proteases.

Authors:  M Luisa Iruela-Arispe
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.